ArticleEuropean journal of nuclear medicine and molecular imaging2015
⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.
Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04504565 (The Efficacy of 99mTc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of 99mTc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma
Who cites it
8 citing papers in PubMed.
- Prospective study ofThoracic cancer · 2024Article
- Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.International journal of molecular sciences · 2024Review
- Evaluation of integrin αCancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αPharmaceutics · 2022Article
- Advances in Clinical Oncology Research onFrontiers in oncology · 2022Review
- Integrin αVβOncology letters · 2018Article
- Evaluation ofAnnals of nuclear medicine · 2017Article
- (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMonitoring of response to neoadjuvant chemotherapy (NCT) is important for optimal management of patients with breast cancer. (99m)Tc-3PRGD2 SPECT is a newly developed imaging modality for evaluating tumor vascular status. In this study, we investigated the application of (99m)Tc-3PRGD2 SPECT in evaluating therapy response to NCT in patients with stage II or III breast cancer.
methodsThirty-three patients were scheduled to undergo (99m)Tc-3PRGD2 SPECT at baseline, after the first and second cycle of NCT. Four patients had extremely low (99m)Tc-3PRGD2 uptake at baseline, and were not included in the subsequent studies. Changes in tumor to nontumor (T/N) ratio were compared with pathological tumor responses classified using the residual cancer burden system. Receiver operator characteristic analysis was used to compare the power to identify responders between the end of the first and the end of the second cycle of NCT. The impact of breast cancer subtype on (99m)Tc-3PRGD2 uptake was evaluated. The correlation between (99m)Tc-3PRGD2 uptake and pathological tumor response was also evaluated in each breast cancer subtype.
resultsSurgery was performed after four cycles of NCT and pathological analysis revealed 18 responders and 15 nonresponders. In patients with clearly visible (99m)Tc-3PRGD2 uptake at baseline, the sensitivity, specificity, and negative predictive value of (99m)Tc-3PRGD2 SPECT were 86.7 %, 85.7 % and 86.7 % after the first cycle of NCT, and 92.9 %, 93.3 % and 93.3 % after the second cycle, respectively. Among these patients, the HER-2-positive group demonstrated both higher T/N ratios and a greater change in T/N ratio than patients with other breast cancer subtypes (P < 0.05). A strong correlation was found between changes in T/N ratio and pathological tumor response in the HER-2-positive group (P < 0.03).
conclusion(99m)Tc-3PRGD2 SPECT seems to be useful for determining the pathological tumor response in patients with stage II or III breast cancer undergoing NCT, especially those with the HER-2-positive subtype.
Indexed as
Identifiers
25947573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.